MeSci
ME/CFS since 1995; activity level 6?
- Messages
- 8,231
- Location
- Cornwall, UK
Just seen on Physician's First Watch:
FDA Adds Boxed Warning to Two Cancer Drugs
By the Editors
The labels of the immune-suppressing, anti-cancer drugs ofatumumab (Arzerra) and rituximab (Rituxan) will be updated with a boxed warning noting an increased risk for reactivation of hepatitis B virus infection. Rituximab is used to treat non-Hodgkin lymphoma, and both drugs are used for chronic lymphocytic leukemia.
In its MedWatch safety alert, the FDA offers guidance for clinicians to help decrease the risk for HBV reactivation with these agents.
Link(s):
FDA MedWatch safety alert (Free) http://click.jwatch.org/cts/click?q=227%3B67896262%3BzeBeGPRQRwWxrV7BojPq0%2FwzDWmDRFf98ZoSAu1SKQQ%3D
Background: NEJM Journal Watch summary on HBV reactivation after rituximab (Your NEJM Journal Watch registration required) http://click.jwatch.org/cts/click?q=227;67896262;zeBeGPRQRwWxrV7BojPq09FCdigMlZPW8ZoSAu1SKQQ=
FDA Adds Boxed Warning to Two Cancer Drugs
By the Editors
The labels of the immune-suppressing, anti-cancer drugs ofatumumab (Arzerra) and rituximab (Rituxan) will be updated with a boxed warning noting an increased risk for reactivation of hepatitis B virus infection. Rituximab is used to treat non-Hodgkin lymphoma, and both drugs are used for chronic lymphocytic leukemia.
In its MedWatch safety alert, the FDA offers guidance for clinicians to help decrease the risk for HBV reactivation with these agents.
Link(s):
FDA MedWatch safety alert (Free) http://click.jwatch.org/cts/click?q=227%3B67896262%3BzeBeGPRQRwWxrV7BojPq0%2FwzDWmDRFf98ZoSAu1SKQQ%3D
Background: NEJM Journal Watch summary on HBV reactivation after rituximab (Your NEJM Journal Watch registration required) http://click.jwatch.org/cts/click?q=227;67896262;zeBeGPRQRwWxrV7BojPq09FCdigMlZPW8ZoSAu1SKQQ=